; and ; and (3) by adding at the end the following new subparagraph: (F) in the case of a drug contained in the applicable list, a certification that the registrant has— (i) identified every other establishment where manufacturing is performed for the drug; and (ii) notified each known foreign establishment engaged in the manufacture, preparation, propagation, compounding, or processing of the drug, including the active pharmaceutical ingredient, of the inclusion of the drug in the list and the obligation to register. . (c) Quarterly reporting on amount of drugs manufactured Section 510(j)(3)(A) of the Federal Food, Drug, and Cosmetic Act (as added by section 3112 of the CARES Act ( Public Law 116–136 )) is amended by striking annually and inserting once during the month of March of each year, once during the month of June of each year, once during the month of September of each year, and once during the month of December of each year . 30516. Recommendations to encourage domestic manufacturing of critical drugs (a) In general Not later than 14 days after the date of enactment of this Act, the Secretary shall enter into an agreement with the National Academies of Sciences, Engineering, and Medicine (referred to in this section as the National Academies ) under which, not later than 90 days after the date of entering into the agreement, the National Academies will— (1) establish a committee of experts who are knowledgeable about drug and device supply issues, including— (A) sourcing and production of critical drugs and devices; (B) sourcing and production of active pharmaceutical ingredients in critical drugs; (C) the raw materials and other components for critical drugs and devices; and (D) the public health and national security implications of the current supply chain for critical drugs and devices